New immunoglobulin for treatment of anthrax | Новый иммуноглобулин для лечения сибирской язвы
2009
Borovskoj, D.V. | Shevtsov, A.N. | Darmov, I.V. | Lub, M.Yu. | Zajtseva, G.A. | Drobkova, A.V. | Dolmatov, V.Yu., Ministry of Public Health and Social Development (Russian Federation). Kirov Research and Development Inst. of Hematology and Blood Transfusion
A new high-effective anti-anthrax gamma-globulin (AAG) has been developed for internal administration produced from human blood plasma for arresting toxemia when epidemics and epizootics occur caused by using Bacillus anthracis as striking biological weapons. AAG is a 100% gamma-globulin comprising at least 95% LgG with an antibody titer to protective antigen in EIA being 1:1600, anti-complementary activity 50 units of complements per 1 mg of protein and index of preventive properties of at least 04. The prophylactic and therapeutic efficacy of this preparation has been comparatively studied and currently used equine anti-anthrax immunoglobulin (EAI) for intramuscular administration having side effects. The protective properties of immunoglobulins were comparatively studied on guinea pigs to which AAG and EAI were administered at the same doses. The observation time was 10 days. The efficiency of AAG was 50%, EAI was 60%. It is supposed that the highest prophylactic efficiency of EAI is achieved by great content of specific antibodies in heterogeneous immunoglobulin produced from blood serum of horses hyperimmunized against anthrax. The therapeutic efficiency of the two immunoglobulins as a means for monotherapy for anthrax was 70%. It is concluded that the protective properties of the preparation are comparative to EAI, besides, it is apyrogenic, non-toxic and does not give a serum shock
显示更多 [+] 显示较少 [-]